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This multicentre phase II study was aimed at investigating the activity and safety of pegylated liposomal doxorubicin (PLD) and
gemcitabine (GEM) as front-line therapy in a large series of chemotherapy-naı ¨ve recurrent/metastatic breast cancer patients. From
June 2003 to December 2006, a total of 71 recurrent/metastatic breast cancer patients were enrolled. Median age was 63 years
(range¼37–79), and 31 patients (43.7%) were X65 years old. Patients received PLD, 25mgm
 2, day 1, followed by GEM,
800mgm
 2, days 1 and 8, q21. Response was evaluable in 64 cases. Eight complete (12.5%) and 17 partial responses (26.6%) were
registered, with an overall response rate of 39.1%. Thirty patients (46.9%) experienced stable disease, with an overall clinical benefit
of 85.9%. Median time to progression (TTP) was 11 months, whereas median overall survival (OS) was not reached. The rate of
1- and 2-year OS was 79 and 61%, respectively. A total of 443 courses were evaluable for toxicity: grade 3 and 4 neutropaenia
affected 14 patients (20.3%) and 3 patients (4.3%), respectively. Grade 3 and 4 palmar-plantar erythrodysesthesia syndrome was
documented in five cases (7.2%) and one case (1.4%), whereas grade 3 and 4 mucositis occurred in six cases (8.7%) and two cases
(2.9%), respectively. Grade 2 cardiac toxicity was observed in only one case. Interestingly enough, there was no difference in the
percentage and severity of either haematological or non-haematological toxicity according to the age of the patients (o65 vs X65
years). We confirmed in a large, very homogenous study sample of chemotherapy-naı ¨ve recurrent/metastatic breast cancer patients
the efficacy and safety of PLD/GEM combination, providing response rates, median TTP and OS values comparable with those
achieved with more toxic combinations.
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Breast carcinoma is the most frequent cancer, and the second most
leading cause of death from cancer in women (Jemal et al, 2007).
Approximately 27% of patients are initially diagnosed with already
metastatic disease, and almost 30% of lymph node-negative and
up to 60–70% of lymph node-positive cases will develop recurrent
disease within 5 years from initial diagnosis (Paridaens, 2000;
Jemal et al, 2007) In this clinical setting, the prognosis is
unfavourable, with a median overall survival (OS) of 1.5–2 years
(Cardoso et al, 2002). Therefore, special attention has to be paid to
the issue of quality of life preservation, as prolongation of survival
and palliation of symptoms remain the only realistic objectives.
Among the drugs or drug combinations currently proposed for
recurrent/metastatic breast cancer, anthracyclines and taxanes are
considered the most effective ones, with rates of overall response
between 46 and 88% (Mavroudis et al, 2000; Morales et al, 2004;
Gamucci et al, 2007; Von Minckwitz, 2007); however, the use of
anthracyclines in clinical practice is limited by drug-associated
toxicity, particularly myelosuppression and cardiotoxicity (Robert
et al, 2004). Indeed, the replacement of doxorubicin with
epirubicin or pegylated liposomal doxorubicin (PLD) has strongly
improved the pattern and severity of adverse effects (Robert et al,
2004; O’Brien, 2008); moreover, also the proper use of growth
factor support (Morales et al, 2004) or the adoption of weekly
schedules for combinations of anthracyclines/taxanes (Gamucci
et al, 2007) has been proposed to overcome haematological
toxicity.
Besides PLD, whose activity as a single agent in recurrent/
metastatic breast cancer has been documented in several phase II
studies (response rate¼31–38%) (Ranson et al, 1997; Lyass et al,
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s2000; O’Brien et al, 2004), gemcitabine (GEM) has also been
reported to provide encouraging response rates (range¼25–37%)
in this clinical setting (Carmichael et al, 1995; Blackstein et al,
2002). Moreover, the different mechanisms of action of the two
drugs, which have been shown to synergise in in vitro and in vivo
models (Chow et al, 2000; Gallo et al, 2006), as well as the non-
overlapping toxicity profiles, further strengthened the rationale for
their combination. Indeed, combined administration of PLD/GEM
has been successfully investigated in ovarian cancer (Ferrandina
et al, 2005), as well as in recurrent/metastatic breast cancer patients;
in particular, in the latter subset of patients, an overall response rate
between 26 and 52% (median duration of response¼5.5–7
months), with an acceptable toxicity profile, has been reported in
three phase II studies (Rivera et al, 2003; Fabi et al, 2006; Ulrich-
Pur et al, 2007). However, the relatively small study samples, as well
as the heterogeneity of the series, which often included a discrete
proportion of patients receiving PLD/GEM combination as second
line or even third or fourth line of treatment, might limit the
reliability of comparison across the studies and hamper the value of
data on the efficacy and the overall toxicity.
The aim of this study was to investigate the activity and safety of
PLD/GEM combination as front-line therapy in a large, homo-
genous series of recurrent/metastatic breast cancer patients. The
evaluation of response according to oestrogen (ER) and proges-
terone (PR) hormone receptors, as well as erbB2/neu status, has
also been studied. Although trastuzumab is the indicated therapy
for erbB2/neu-positive cases, we did not consider the addition of
this drug to the combination, given the main objective of the study;
indeed, the inclusion of trastuzumab in the subgroup of erbB2/
neu-positive patients would have made the analysis of the data
difficult, especially considering the underlying higher suscept-
ibility of erbB2/neu-positive tumours to both anthracyclines and
trastuzumab.
MATERIALS AND METHODS
Study design
This is a multicentre phase II study aimed at evaluating the activity
of the combination of PLD and GEM as first-line treatment of
chemotherapy-naı ¨ve recurrent/metastatic breast cancer patients.
The primary end point was the assessment of PLD/GEM efficacy
in terms of clinical response and time to progression (TTP).
Overall survival and the safety and tolerability of the combination
were also investigated as secondary end points. The approval of the
local ethic committee was obtained before the start of the trial.
Eligibility
Patients with histologically/cytologically documented recurrent/
metastatic breast cancer who had not been previously treated for
metastatic/recurrent disease were enrolled. Only cases with
radiological evidence of measurable (42cm) or evaluable disease
lesions were eligible for the study. Previous adjuvant and/or
neoadjuvant chemotherapy was allowed if completed 41 year
before the inclusion in the study: in particular, previous treatment
with anthracyclines was permitted if the cumulative dose did not
exceed 350mgm
 2 for adriamycin, 450mgm
 2 for epirubicin, and
75mgm
 2 for mitoxanthrone. Further entry criteria were age 18–
75 years, Eastern Cooperative Oncology Group performance status
p2, life expectancy 43 months, absolute neutrophil count (ANC)
X1500ml
 1, platelet (PLT) count 4100000ml
 1, haemoglobin
levels 410g%, bilirubin and creatinine levels less than 1.5 times
the upper limit of normal, normal cardiac function (left ventricular
ejection fraction (LVEF) X50%), normal respiratory function, and
alkaline phosphatase p2.5-fold the upper normal limit. All
patients were required to provide a written informed consent.
Exclusion criteria were as follows: previous or concurrent
malignancies at other sites with the exception of basal or
squamous cell carcinoma of the skin and cone biopsed carcinoma
in situ of the uterine cervix; Brenner’s and borderline ovarian
tumours; symptomatic CNS metastases; and uncontrolled severe
infection and/or medical problems unrelated to malignancy that
would limit full compliance with the study or expose the patient to
extreme risk. Additional exclusion criteria were as follows:
previous chemotherapy with PLD or GEM, and administration of
other investigational cytotoxic drugs within 30 days before entry
into the study.
Treatment plan
Within 14 days from the beginning of the study treatment,
patients were submitted to a complete clinical evaluation including
medical history, laboratory tests with complete blood cell count,
and serum chemistry, Ca 15-3 level, and urinalysis. Bone
scintigraphy, CT scan, and chest X-rays were also performed.
Then, PLD, 25mgm
 2, diluted in 250ml of 5% dextrose, was
administered on day 1 by a 60min i.v. infusion, followed by GEM,
800mgm
 2, diluted in 250ml of 0.9% saline solution, on days 1
and 8 by a 30min i.v. infusion; cycles were repeated every 21 days,
until progression of disease, unacceptable toxicity, patients’
refusal, or at physician’s discretion. All patients received
dexamethasone (8mg) and ranitidine (50mg) before drug
administration.
Response and toxicity assessment
The evaluation of response was performed every three cycles by
the same clinical and imaging approach used for the baseline
assessment. Clinical response was assessed according to the
RECIST criteria (Therasse et al, 2000). Response rates were
calculated, including 95% confidence intervals (95% CI). Clinical
benefit was defined as the overall number of complete responses,
partial responses, and stabilisation of disease. Patients who
received at least two cycles of combination treatment were
evaluable for efficacy, and patients who received at least one dose
of chemotherapy were evaluable for toxicity.
Chemotherapy-induced toxicity was graded according to the
common toxicity criteria of National Cancer Institute (1999).
Complete blood count and PLT count were performed on a weekly
basis; ECG was performed at every cycle, whereas echocardio-
graphy was performed every 2 cycles and at the end of the
treatment. A multigated angiogram was planned if the echocardio-
graphy registered an LVEF reduction 410% (D’Agostino et al,
2003). A 25% dose reduction of both drugs was planned in the
case of ANC o500ml
 1 and/or PLT count o25000ml
 1 on the day
of planned drug administration. A 25% dose reduction of PLD
was also planned in the case of grade 1 or 2 palmar-plantar
erythrodysesthesia syndrome (PPE) or mucositis persisting for 42
weeks. In the case of ANC o1500ml
 1 and/or PLT count
o100000ml
 1 on the day of planned therapy, 1 week delay of
drug administration was planned without dose adjustment.
Gemcitabine administration on day 8 was omitted in the case of
G4 neutropaenia, febrile neutropaenia, G3/G4 thrombocytopaenia
or anaemia, or G3/G4 non-haematological toxicity (excluding
alopecia or nausea/vomiting).
To reliably assess the safety of PLD/GEM combination, the
prophylactic use of growth factors was not allowed, and
granulocyte-colony stimulating factor (G-CSF) and/or epoetin
were administered in the therapeutic setting only in the case of
febrile neutropaenia or grade 3–4 neutropaenia lasting 45 days,
haemoglobin levels o10g% (Rizzo et al, 2002), or at the
physician’s discretion. Pyridoxine was not used as a prophylactic
strategy to prevent PPE.
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sCriteria for treatment discontinuation
In patients who had to delay treatment for 42 weeks, treatment
was discontinued. Treatment was also discontinued in the case of
severe hypersensitivity reaction, grade 3 or 4 PPE or mucositis
persisting for 42 weeks, reduction of LVEF 420% from baseline
value, in the case of symptomatic congestive heart failure, or in any
case of 4G3 non-haematological toxicity (with the exception of
alopecia or nausea/vomiting). Treatment was also discontinued in
the case of patient’s refusal.
Statistical analysis
The sample size was calculated on the basis of the two-stage design
by Simon (1989). The design tested the null hypothesis that the
true response rate for this population would improve by
approximately 40%, that is, from 30% to the clinically relevant
alternative of 50%, using an a error of 0.05 and a b error of 0.1.
Thus, the first step will include 24 patients; if 48 responses are
recorded, the study would enrol additional 39 patients up to a total
of 63 patients. The regimen would be considered active if 424
responses are recorded. Considering a dropout rate of approxi-
mately 10%, at least 70 patients were planned to be enrolled.
Overall survival was defined as time elapsed between start of PLD/
GEM treatment and date of death or the date last seen. Time to
progression was defined as the time elapsed between start of PLD/
GEM treatment and documentation of progressive disease or the
last seen. Median and life tables were computed using the product-
limit estimate of Kaplan and Meyer (1958).
RESULTS
Patient characteristics
From June 2003 to December 2006, a total of 71 recurrent/
metastatic breast cancer patients were enrolled into this phase II
multicentre clinical trial.
Patient characteristics at study entry are given in Table 1.
Median age was 63 years (range¼37–79), and 31 patients (43.7%)
were X65 years old.
Forty-one (57.7%) patients had been treated with adjuvant
radiotherapy, 41 patients had received adjuvant hormone therapy,
and 49 (69.0%) had been administered neoadjuvant/adjuvant
chemotherapy: overall, at the time of study entry, 29 (40.8%) had
already been treated with anthracycline-containing regimens. The
vast majority of cases (n¼62, 87.3%) had visceral localisation of
recurrent/metastatic disease, including 6 cases of liver metastasis,
7 cases of lung metastasis, and 49 cases with multiple sites of
disease. The expression of ER, PR, and erbB2/neu was available in
67 cases: ER or PR positivity was documented in 43 (64.2%) and
37 (55.2%) cases, respectively, whereas 35 patients (52.2%) had
erbB2/neu-overexpressing (2þ/3þ score) tumours (see Table 1).
Response to treatment and clinical outcome
Evaluation of response according to the intent-to-treat analysis
and assessable population is summarised in Table 2. Seven patients
were not considered evaluable for response due to early
Table 1 Patient characteristics at study entry
Characteristics No. (%)
Patients enrolled 71
Age (years) (median (range)) 63 (37–79)
ECOG performance status 0/1/2 53/16/2
Site of recurrence
Liver 6 (8.4%)
Lung 7 (9.8%)
Mixed 49 (80.3%)
Bone 5 (7.0%)
Axilla 4 (5.6%)
Previous treatment
Adjuvant RT 41 (57.7%)
Adjuvant HT 41 (57.7%)
Adjuvant/neoadjuvant CT 49 (69.0)
Anthracycline-based CT 29 (40.8%)
ER status (by immunohistochemistry)
Positive 44 (61.9%)
Unknown 4 (5.6%)
PR status (by immunohistochemistry)
Positive 37 (52.1%)
Unknown 4 (5.6%)
ErbB2/neu status (by immunohistochemistry)
Negative or 1+ 32 (45.1%)
2+ 14 (19.7%)
a
3+ 21 (29.6)
Unknown 4 (5.6%)
ECOG¼Eastern Cooperative Oncology Group; RT¼radiotherapy; HT¼hormone
therapy; CT¼chemotherapy.
aTen out of 14 erbB2/neu 2+ cases showed DNA
amplification at FISH.
Table 2 Clinical response in the overall series
Intention to treat (n¼71) Assessable (n¼64)
No. % (95% CI) No. % (95% CI)
Response
Complete (CR) 8 11.3 (4.1, 18.5) 8 12.5 (4.4, 20.6)
Partial (PR) 17 23.9 (14.0, 33.8) 17 26.6 (15.7, 37.3)
Overall response 25 35.2 (2.4, 46.3) 25 39.1 (27.1, 50.9)
Stable disease (SD) 30 42.2 (30.9, 53.5) 30 46.9 (34.7, 59.1)
Progression (PD) 9 12.7 (5.1, 20.3) 9 14.1 ( 5.6, 22.6)
Not available 7 9.9 — —
Clinical benefit (CR, PR, SD) 55 77.5 (67.8, 87.2) 55 85.9 (77.4, 94.4)
Time to response (months)(median (range)) 3.0 (2.0–7.0)
Duration of response (months) (median (range)) 4.7 (2.0–8.0)
Duration of SD (months) (median (range)) 2.5 (1.5–5.2)
Duration of clinical benefit (months) (median (range)) 4 (2–11)
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severe allergic reaction during the first administration of PLD
(n¼2), and patient refusal (n¼1). Therefore, at the time of
analysis, response was evaluable in 64 cases: 8 complete responses
(12.5%) and 17 partial responses (26.6%) have been registered,
with an overall response rate of 39.1%. The median duration of
response was 4.7 months (range¼2.0–8.0), and among the
responders, 6 had response lasting more than 6 months. Thirty
patients (46.9%) experienced stabilisation of disease, with a rate of
overall clinical benefit (complete responses, partial responses, and
stabilisation of disease) of 85.9%. The median duration of stable
disease and clinical benefit was 2.5 months (range¼1.5–5.2) and
4 months (range¼2–11), respectively.
The proportion of responders according to the site (visceral vs
not visceral localisation) of disease was not statistically significant
(60.0 vs 75.0%, P-value¼0.6). In addition, there was no difference
in the rate of overall response in patients who had already been
treated with anthracyclines vs anthracycline patients (38.5 vs
42.4%, P-value¼0.7).
The percentage of cases achieving complete or partial response
to treatment was significantly higher in cases showing immuno-
histochemically assessed overexpression of erbB2/neu than in
cases that do not express or express 1þ erbB2/neu (51.4 vs 24.1%,
P-value¼0.039). On the other hand, no difference in the response
rate according to ER and PR status was documented (data not
shown).
Follow-up data were available for all patients. As of November
2007, median follow-up duration was 15 months (range¼1–44).
During the follow-up period, progression and death of disease
were observed in 35 and 23 cases, respectively. Median TTP was 11
months, whereas the median OS was not reached (Figure 1). The
rate of 1- and 2-year OS was 79 and 61%, respectively.
Toxicity
A total of 443 courses were evaluable for toxicity, with a median
number of 6 cycles (range¼1–17) administered per patient
(Table 3); 17 patients (24.6%) received 48 cycles of treatment.
The data on toxicity were available in 69 patients, as in 2 cases
chemotherapy administration had to be discontinued early owing
to the occurrence of severe allergic reaction to PLD during the
administration of the first treatment course. In particular, both
patients experienced sudden occurrence of cutaneous erythema
(face and hands), arterial hypertension, dyspnea, and tachycardia
after a few minutes since the beginning of PLD; the infusion was
stopped and the patients were treated with steroids and H2-
antihistamines with the regression of the described symptoms.
Both patients refused to continue the treatment.
The median cumulative dose of PLD per patient was 227mgm
 2
(range¼36–630mgm
 2), whereas the median cumulative dose
of GEM per patient was 13600mgm
 2 (range¼1200–
36800mgm
 2) (Table 3). The delivered dose of PLD and GEM
was 94 and 85% of the projected dose, respectively.
In 10 patients (14.5%), dose reduction was required, mostly
because of haematological toxicity; 1 week delay was necessary in
10 patients (14.5%). There were six patients discontinuing
treatment because of chemotherapy toxicity, including five cases
of grade 3 PPE and one case of grade 2 cardiotoxicity.
As far as haematological toxicity is concerned (Table 4),
myelosuppression was usually brief and manageable with dose
adjustments or treatment delay. Grade 3 and 4 neutropaenia
affected 14 (20.3%) and 3 (4.3%) patients; only 1 (1.4%) case of
febrile neutropaenia was registered. Eight (11.6%) required
administration of G-CSF.
Grade 3 anaemia and grade 3 thrombocytopaenia were
documented in only three cases (4.3%) and one case (1.4%),
respectively. Recombinant human erythropoietin (rHu-Epo) was
administered to six patients (8.7%) As far as non-haematological
toxicity is concerned, grade 3 asthenia was registered in only four
patients (5.8%) and nausea/vomiting (grade 3) occurred in one
patient.
Hepatotoxicity was infrequent and mild (grade 1 or 2¼10.1%).
Moderate and severe PPE was documented in five cases (7.2%) and
1 case (1.4%), respectively, whereas grade 3 and 4 mucositis
occurred in six cases (8.7%) and two cases (2.9%), respectively.
Complete alopecia was documented in only one case.
Although our series included 29 cases (40.8%) who had been
previously treated with anthracyclines and 13 cases who were X65
years old and had received previous radiotherapy to the chest,
grade 2 cardiac toxicity was observed in only one case: in
particular, this patient was 70 years old and had already received
radiation to the left chest wall and previous treatment with
anthracyclines. A reduction of 20% of LVEF from baseline value
was registered after three cycles of PLD treatment (cumulative PLD
0
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Figure 1 Time to progression and OS curves in the whole population.
Table 3 Study drug administration details
Total cycles administered 443
Number of cycles per patient (median (range)) 6 (1–17)
Cumulative PLD dose (mgm
 2) (median (range)) 227 (36–630)
Cumulative GEM dose (mgm
 2) (median (range)) 13600 (1200–36800)
Patients with dose reduction (no. (%)) 10 (14.5%)
Patients with treatment delay (no. (%)) 10 (14.5%)
Patients discontinuing treatment owing to toxicity
(no. (%))
6 (8.7%)
GEM¼gemcitabine; PLD¼pegylated liposomal doxorubicin.
Table 4 Overall toxicity (per patient) (n¼69)
Grade 1 Grade 2 Grade 3 Grade 4
Toxicity No. % No. % No. % No. %
Leukopaenia 4 5.8 16 23.2 12 17.4 1 1.4
Neutropaenia 5 7.2 19 27.5 14 20.3 3 4.3
Anaemia 17 24.6 10 14.5 3 4.3 0 —
Thrombocytopaenia 5 7.2 4 5.8 1 1.4 0 —
Fatigue 12 17.4 9 13.0 4 5.8 0 —
Nausea/vomiting 12 17.4 8 11.6 1 1.4 0 —
Liver 4 5.8 3 4.3 0 — 0 —
PPE 4 5.8 8 11.6 5 7.2 1 1.4
Mucositis 6 8.7 11 15.9 6 8.7 2 2.9
PPE¼palmar-plantar erythrodysesthesia syndrome.
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 2), and the treatment was interrupted because
of patient’s refusal. Interestingly enough, there was no difference
in the percentage and severity of either haematological or
non-haematological toxicity according to the age of the patients
(o65 vs X65 years) (data not shown).
DISCUSSION
We confirmed in a large, very homogenous study sample the
efficacy and safety of PLD/GEM combination in chemotherapy-
naı ¨ve recurrent/metastatic breast cancer patients. In particular, we
showed that PLD/GEM combination provides an overall response
rate of 39.1%, which is in the range of results reported by previous
studies (Rivera et al, 2003; Fabi et al, 2006; Ulrich-Pur et al, 2007).
Moreover, we reported the achievement of disease stabilisation in
46.9% of cases for an overall clinical benefit of almost 86%, which
currently represents the best figure obtained with this regimen
across the available phase II studies.
As previously reported (Rivera et al, 2003; Fabi et al, 2006), the
overall response rate in our study did not vary according to
previous exposure to anthracyclines or disease sites, whereas it
was significantly higher in cases whose tumours overexpress
erbB2/neu, as compared with erbB2/neu-negative cases. Amplifi-
cation and/or overexpression of erbB2/neu has been recognised as
a marker of susceptibility to treatment with anthracyclines
(Moliterni et al, 2003), although several observations argue against
a direct role for erbB2/neu alterations in anthracycline sensitivity
(Sledge, 2001); in particular, it has been speculated that the role of
erbB2/neu overexpression as a predictor of response to anthra-
cyclines might reflect the close location of erbB2/neu and the gene
coding for topoisomerase IIa, which is the molecular target of
topoisomerase II inhibitors, such as anthracyclines, and has
already been shown to be involved in anthracycline susceptibility
(Trost Jorgensen et al, 2007). Co-amplification of erbB2/neu and
topoisomerase IIa has recently been suggested to be able to define
a subgroup of high-risk breast cancer patients who benefit the
most from anthracycline treatment (Tanner et al, 2006). In this
context, the most important clinical impact of our findings rely on
the potential improvement of response rate and clinical outcome,
deriving from selection of patients to be triaged to PLD-based
regimens on the basis of concomitant assessment of erbB2/neu and
topoisomerase IIa.
With the limits inherent to the comparison across non-
randomised phase II studies, our data on median TTP and OS
compare well with the results obtained using other drug combina-
tions including PLD (Addeo et al, 2007) or with epirubicin/taxane
regimens (Mavroudis et al, 2000; Morales et al, 2004; Gamucci et al,
2007; Von Minckwitz, 2007). These data become even more relevant
considering the favourable toxicity profile of this regimen in
comparison with epirubicin/docetaxel combinations: indeed the
profile of haematological toxicity was quite acceptable with
percentages of moderate/severe neutropaenia lower than those
reported by other authors, despite the use of G-CSF in a relatively
low proportion of cases compared with trials that utilised
prophylactic growth factor support (Morales et al, 2004).
On the other hand, we found a slightly higher percentage of
mucositis/PPE than that reported with the same regimen; these
findings could be related to the decision not to pre-medicate or
treat PPE with pyridoxine: moreover, it cannot be excluded that
the high proportion of mucositis/PPE, whose incidence and
severity parallel the administered cumulative drug dose, might
be also sustained by our strategy of continuing treatment until
progression, which led to administer 48 cycles of PLD/GEM in
24.6% of cases.
Moreover, we observed only one case of cardiac toxicity,
despite the fact that 41% of patients had already been treated
with anthracyclines, and approximately 30% were X65 years old;
in addition, 41.9% had also been irradiated in the adjuvant
setting; these data confirm the cardiac safety of PLD-based
regimens (Robert et al, 2004; O’Brien, 2008), and support its safe
use also in anthracycline-exposed older patients. Indeed, there
was neither any difference in the haematological toxicity nor in
the non-haematological toxicity in patients aged X65 years
compared with younger ones: this is a very relevant clinical issue
considering that no standard chemotherapy has been established
for elderly patients with recurrent/metastatic breast cancer, and
efforts are constantly made to maintain the drug combination
approach (Cianfrocca and Gradishar, 2007), but not at the expense
of safety.
Finally, also alopecia, a treatment-related side effect hardly
tolerable in patients also required to cope with the distress of
disease relapse, has been reported as complete in only one case,
and this is expected to contribute to preserve patient’s quality of
life, as shown by Fabi et al (2006).
In conclusion, we showed that PLD/GEM combination is active
in recurrent/metastatic breast cancer patients, providing response
rates, and above all median TTP and OS values comparable with
those achieved with more toxic combinations (Von Minckwitz,
2007). In particular, the very low incidence of cardiac toxicity even
in older patients already irradiated and treated with anthracyclines
allows one to propose to a larger subset of patients a re-challenge
with this class of agents, which remain the most active drugs in the
management of this disease.
Finally, the possibility to take advantage of the assessment of
erbB2/neu and topoisomerase IIa expression to select the patients
most likely to benefit from PLD/GEM combination, and possibly
from the addition of trastuzumab in erbB2/neu-positive cases,
emphasises the need to administer chemotherapy on a patient by
patient basis, an issue that becomes clinically crucial in the subset
of salvage treatment.
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